Functional anticholinergic activity of drugs classified as strong and moderate on the anticholinergic burden scale on bladder and ileum.
anticholinergic burden
bladder
constipation
ileum
urinary retention
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
revised:
15
07
2024
received:
02
03
2024
accepted:
05
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Several medications are commonly administered to older Japanese patients. Since some of them have not been included in previously developed scales to estimate the anticholinergic burden, we have developed a new muscarinic receptor binding-based anticholinergic burden scale. This study aimed to investigate the functional inhibitory effects of 60 medications, classified as anticholinergic burden scales 3 and 2 by the anticholinergic burden scale, on muscarinic receptor-mediated contractions in the bladder and ileum. The relaxation response induced by these drugs on isolated rat bladders and ileum smooth muscles constricted by carbachol was assessed using the organ bath method. All drugs inhibited smooth muscle contractile responses induced by the muscarinic receptor activation in a concentration-dependent manner in the rat bladder and ileum. Notably, variations were observed in the relaxation responses of the drugs, and the function EC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.
Références
Delara M, Murray L, Jafari B, et al. Prevalence and factors associated with polypharmacy: a systematic review and meta‐analysis. BMC Geriatr. 2022;22(1):601. doi:10.1186/s12877‐022‐03279‐x
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443‐452. doi:10.1007/s41999‐021‐00479‐3
Mabuchi T, Hosomi K, Yokoyama S, Takada M. Polypharmacy in elderly patients in Japan: analysis of Japanese real‐world databases. J Clin Pharm Ther. 2020;45(5):991‐996. doi:10.1111/jcpt.13122
Lavrador M, Castel‐Branco MM, Cabral AC, Verissimo MT, Figueiredo IV, Fernandez‐Llimos F. Association between anticholinergic burden and anticholinergic adverse outcomes in the elderly: pharmacological basis of their predictive value for adverse outcomes. Pharmacol Res. 2021;163:105306. doi:10.1016/j.phrs.2020.105306
Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099‐1105. doi:10.1001/archinte.161.8.1099
Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug‐related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481‐1486. doi:10.1177/0091270006292126
Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J am Geriatr Soc. 2008;56(7):1333‐1341. doi:10.1111/j.1532‐5415.2008.01737.x
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508‐513. doi:10.1001/archinternmed.2007.106
Braithwaite E, Todd OM, Atkin A, et al. Interventions for reducing anticholinergic medication burden in older adults—a systematic review and meta‐analysis. Age Ageing. 2023;52(9). doi:10.1093/ageing/afad176
Stenback J, Tiisanoja A, Syrjala AM, Komulainen K, Hartikainen S, Ylostalo P. High anticholinergic burden and hyposalivation and xerostomia in the elderly. Acta Odontol Scand. 2023;81(6):436‐442. doi:10.1080/00016357.2023.2166105
Yamada S, Mochizuki M, Atobe K, Kato Y. Pharmcokinetic and pharmacodynamic considerations for the anticholinergic burden scale of drugs. Geriatr Gerontol Int. 2024;24(Suppl 1):81‐87. doi:10.1111/ggi.14706
Stewart C, Yrjana K, Kishor M, et al. Anticholinergic burden measures predict older people's physical function and quality of life: a systematic review. J am Med Dir Assoc. 2021;22(1):56‐64. doi:10.1016/j.jamda.2020.05.065
Taylor‐Rowan M, Alharthi AA, Noel‐Storr AH, et al. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment. Cochrane Database Syst Rev. 2023;12(12):CD015405. doi:10.1002/14651858.CD015405.pub2
Bishara D. Managing drugs with anticholinergic activity. Drug Ther Bull. 2023;61(9):135‐139. doi:10.1136/dtb.2022.000066
Rodriguez‐Ramallo H, Baez‐Gutierrez N, Prado‐Mel E, Alfaro‐Lara ER, Santos‐Ramos B, Sanchez‐Fidalgo S. Association between anticholinergic burden and constipation: a systematic review. Healthcare (Basel). 2021;9(5):581. doi:10.3390/healthcare9050581
Stewart C, Taylor‐Rowan M, Soiza RL, Quinn TJ, Loke YK, Myint PK. Anticholinergic burden measures and older people's falls risk: a systematic prognostic review. Ther Adv Drug Saf. 2021;12:20420986211016645. doi:10.1177/20420986211016645
Taylor‐Rowan M, Edwards S, Noel‐Storr AH, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5(5):CD013540. doi:10.1002/14651858.CD013540.pub2
Novella A, Elli C, Ianes A, Pasina L. Anticholinergic burden and cognitive impairment in nursing homes: a comparison of four anticholinergic scales. Drugs Aging. 2023;40(11):1017‐1026. doi:10.1007/s40266‐023‐01058‐w
Kayahan Satis N, Naharci MI. Investigating the association of anticholinergic burden with depression in older adults: a cross‐sectional study. Psychogeriatrics. 2024;24(3):597‐604. doi:10.1111/psyg.13102
Huang WC, Yang AS, Tsai DH, Shao SC, Lin SJ, Lai EC. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case‐case‐time‐control study. BMJ. 2023;382:e076045. doi:10.1136/bmj‐2023‐076045
Shwe PS, Thein PM, Marwaha P, Taege K, Shankumar R, Junckerstorff R. Anticholinergic burden and poor oral health are associated with frailty in geriatric patients undergoing inpatient rehabilitation: a cross‐sectional study. Gerodontology. 2023;40(2):213‐219. doi:10.1111/ger.12635
Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence‐based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558‐564. doi:10.1111/ggi.14619
Miyauchi‐Wakuda S, Kagota S, Maruyama‐Fumoto K, Wakuda H, Yamada S, Shinozuka K. Effect of royal jelly on mouse isolated ileum and gastrointestinal motility. J Med Food. 2019;22(8):789‐796. doi:10.1089/jmf.2018.4340
Yamada S, Chimoto J, Shiho M, et al. Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder. J Pharmacol Exp Ther. 2021;377(2):201‐206. doi:10.1124/jpet.120.000301
Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z‐Lepr (fa)/IzmDmcr rats with metabolic syndrome. Can J Physiol Pharmacol. 2011;89(5):355‐364. doi:10.1139/y11‐029
Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1111/bcpt.13944
Ringdahl B. Selectivity of partial agonists related to oxotremorine based on differences in muscarinic receptor reserve between the guinea pig ileum and urinary bladder. Mol Pharmacol. 1987;31(4):351‐356.
Den C, Nacchia A, Gravina C, et al. Adverse events related to antimuscarinics and beta‐3‐agonist: “real‐life” data from the Eudra‐Vigilance Database. Minerva Urol Nephrol. 2022;74(6):761‐779. doi:10.23736/S2724‐6051.22.04849‐2
Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018;25(10):855‐862. doi:10.1111/iju.13758
Yamada S, Chimoto J, Shiho M, et al. Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder. Int J Urol. 2021;28(12):1298‐1303. doi:10.1111/iju.14696
Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80(24–25):2303‐2307. doi:10.1016/j.lfs.2007.01.053
Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83(5):259‐269. doi:10.1159/000209255
Birder LA. Urinary bladder, cystitis and nerve/urothelial interactions. Auton Neurosci. 2014;182:89‐94. doi:10.1016/j.autneu.2013.12.005